Free Trial
NASDAQ:CYCN

Cyclerion Therapeutics 8/7/2024 Earnings Report

Cyclerion Therapeutics logo
$3.02 -0.12 (-3.82%)
As of 12:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cyclerion Therapeutics EPS Results

Actual EPS
-$0.53
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cyclerion Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cyclerion Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cyclerion Therapeutics' next earnings date is estimated for Tuesday, May 6, 2025, based on past reporting schedules.

Conference Call Resources

Cyclerion Therapeutics Earnings Headlines

Cyclerion Therapeutics files $25M mixed securities shelf
3 US Penny Stocks With Market Caps Over $10M To Consider
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Cyclerion Therapeutics announces update on next stage of growth
See More Cyclerion Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclerion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclerion Therapeutics and other key companies, straight to your email.

About Cyclerion Therapeutics

Cyclerion Therapeutics (NASDAQ:CYCN), a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

View Cyclerion Therapeutics Profile

More Earnings Resources from MarketBeat